These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 11224129)

  • 1. Pharmacological mechanisms and animal models of cognition.
    Dawson GR; Heyes CM; Iversen SD
    Behav Pharmacol; 1992 Aug; 3(4):285-297. PubMed ID: 11224129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropharmacology of cognition and memory: a unifying theory of neuromodulator imbalance in psychiatry and amnesia.
    Vakalopoulos C
    Med Hypotheses; 2006; 66(2):394-431. PubMed ID: 16300905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models of cognitive function.
    Decker MW
    Crit Rev Neurobiol; 1995; 9(4):321-43. PubMed ID: 8829849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
    Goekoop R; Scheltens P; Barkhof F; Rombouts SA
    Brain; 2006 Jan; 129(Pt 1):141-57. PubMed ID: 16251213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models.
    Van Dam D; Marescau B; Engelborghs S; Cremers T; Mulder J; Staufenbiel M; De Deyn PP
    Neurochem Int; 2005 Apr; 46(5):409-22. PubMed ID: 15737439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychopharmacological strategies in the search for cognition enhancers.
    Sanger DJ; Joly D
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():70-4. PubMed ID: 2186417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of human memory and cognition: illustrations from the effects of benzodiazepines and cholinergic drugs.
    Danion JM; Weingartner H; File SE; Jaffard R; Sunderland T; Tulving E; Warburton DM
    J Psychopharmacol; 1993 Jan; 7(4):371-7. PubMed ID: 22291001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection.
    Sarter M; Hasselmo ME; Bruno JP; Givens B
    Brain Res Brain Res Rev; 2005 Feb; 48(1):98-111. PubMed ID: 15708630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Animal cognition: defining the issues.
    Sarter M
    Neurosci Biobehav Rev; 2004 Nov; 28(7):645-50. PubMed ID: 15555674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attention-deficit/hyperactivity disorder: neurophysiology, information processing, arousal and drug development.
    Rowe DL; Hermens DF
    Expert Rev Neurother; 2006 Nov; 6(11):1721-34. PubMed ID: 17144785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs.
    Studzinski CM; Araujo JA; Milgram NW
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):489-98. PubMed ID: 15795058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain cholinergic vulnerability: relevance to behavior and disease.
    McKinney M; Jacksonville MC
    Biochem Pharmacol; 2005 Oct; 70(8):1115-24. PubMed ID: 15975560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
    Brousseau G; Rourke BP; Burke B
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):546-54. PubMed ID: 18179307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging.
    Araujo JA; Studzinski CM; Milgram NW
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):411-22. PubMed ID: 15795050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease.
    Wright JW; Harding JW
    J Renin Angiotensin Aldosterone Syst; 2008 Dec; 9(4):226-37. PubMed ID: 19126664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in cholinergic drugs for Alzheimer's disease.
    Clader JW
    Curr Opin Drug Discov Devel; 1999 Jul; 2(4):311-20. PubMed ID: 19649959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cognitive functions, their development and modern diagnostic methods].
    Klasik A; Janas-Kozik M; Krupka-Matuszczyk I; Augustyniak E
    Przegl Lek; 2006; 63 Suppl 1():29-34. PubMed ID: 17471820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of modafinil on attentional processes in a five-choice serial reaction time test in the rat.
    Waters KA; Burnham KE; O'connor D; Dawson GR; Dias R
    J Psychopharmacol; 2005 Mar; 19(2):149-58. PubMed ID: 15728436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents.
    van der Staay FJ; Rutten K; Bärfacker L; Devry J; Erb C; Heckroth H; Karthaus D; Tersteegen A; van Kampen M; Blokland A; Prickaerts J; Reymann KG; Schröder UH; Hendrix M
    Neuropharmacology; 2008 Oct; 55(5):908-18. PubMed ID: 18674549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.